论文部分内容阅读
目的:探讨血清人附睾分泌蛋白4、癌胚抗原125联合检测诊断卵巢上皮性癌的价值。方法:分别采用ELISA法和电化学发光法测定31例上皮性卵巢癌患者、40例健康体检者(对照组)血清人附睾分泌蛋白4、癌胚抗原125水平。分析2种指标单独和联合检测对上皮性卵巢癌的诊断价值。结果:人附睾分泌蛋白4诊断卵巢上皮性癌的敏感度、特异度分别为70.9%,100.0%;癌胚抗原125诊断卵巢上皮性癌的敏感度、特异度分别为80.6%,85.0%;二者联合检测诊断卵巢上皮性癌的敏感度、特异度分别为93.5%,82.5%。结论:人附睾分泌蛋白4是一种较理想的卵巢上皮性癌肿瘤标志物,联合癌胚抗原125检测可提高卵巢上皮性癌的诊断率。
Objective: To investigate the value of serum human epididymal secreted protein 4 and carcinoembryonic antigen 125 in the diagnosis of epithelial ovarian cancer. Methods: Serum human epididymal secretory protein 4 and carcinoembryonic antigen 125 levels were measured in 31 patients with epithelial ovarian cancer and 40 healthy controls (control group) by ELISA and electrochemiluminescence, respectively. To analyze the diagnostic value of two kinds of indexes separately and jointly on epithelial ovarian cancer. Results: The sensitivity and specificity of human epididymal secretory protein 4 in diagnosing ovarian epithelial carcinoma were 70.9% and 100.0% respectively. The sensitivity and specificity of carcinoembryonic antigen 125 in diagnosing ovarian epithelial carcinoma were 80.6% and 85.0% respectively. The sensitivity and specificity of combined detection and detection of epithelial ovarian cancer were 93.5% and 82.5% respectively. Conclusion: Human epididymal secreting protein 4 is an ideal tumor marker of epithelial ovarian cancer. Combined detection of carcinoembryonic antigen 125 can improve the diagnostic rate of epithelial ovarian cancer.